Understanding the politics of drug pricing in the United States

Everyone says they want more affordable drugs for patients that need them, but people disagree quite a bit on who's to blame for the current status quo of sky-high prescription prices – not to mention how they might be corrected.

To help unpack some of those trends and conflicting perspectives, Brandon Newman, CEO of healthcare analytics firm Xevant, joins host Jonah Comstock on today’s episode of the pharmaphorum podcast.